Eligibility Criteria
- Pathologically proven diagnosis of extensive stage small cell lung cancer
- Patients must be randomized within 9 weeks of last dose of etoposide/platinum or 6 weeks from completion of PCI
- At the time of enrollment, patients must have had measurable disease (per RECIST) and 3 or fewer observable liver metastases and no evidence of progressive disease (per RECIST) at time of enrollment
- History/physical examination within 14 days prior to registration
- Imaging within 42 days prior to registration to include:
- MRI brain with contrast or CT Brain with contrast
- CT chest, abdomen and pelvis or whole body PET/CT scan after the fourth cycle of chemotherapy
- Age ≥ 18
- ECOG Performance Status of 0-2 at the time of registration
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.